Answers are grounded in this paper and cite their sources.
Background: Hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal morbidity and long-term neurodevelopmental impairment, particularly in preterm infants. Early diagnosis remains challenging, and there is growing interest in biomarkers that reflect underlying mechanisms such as neuroinflammation and blood-brain barrier disruption. Objective: To evaluate the diagnostic and prognostic value of selected circulating biomarkers in preterm infants with HIE, with emphasis on a multimarker approach. Methods: This prospective cohort study included 120 preterm infants (gestational age 28-36 weeks), divided into HIE (n = 90) and control (n = 30) groups. Serum levels of NR2 antibodies, endothelin-1, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) were measured at 24-48 hours, day 5-7, and day 14. Statistical analysis included t-test, ANOVA, correlation analysis, logistic regression, and ROC curve analysis. Results: Biomarker levels were significantly higher in the HIE group (p < 0.001). GFAP and NfL showed the highest diagnostic performance (AUC 0.86 and 0.88). The combined model achieved the best accuracy (AUC = 0.89). Biomarker levels correlated with disease severity. Conclusion: A multimarker approach improves diagnostic accuracy and may support early risk stratification and individualized management in preterm infants with HIE.
No takes yet. Share an insight, caveat, or question.
Hadžimuratović et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: